Hideaki Shimada

11.0k total citations · 1 hit paper
382 papers, 8.3k citations indexed

About

Hideaki Shimada is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Hideaki Shimada has authored 382 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Oncology, 126 papers in Pulmonary and Respiratory Medicine and 124 papers in Surgery. Recurrent topics in Hideaki Shimada's work include Esophageal Cancer Research and Treatment (71 papers), Gastric Cancer Management and Outcomes (67 papers) and Cancer Research and Treatments (37 papers). Hideaki Shimada is often cited by papers focused on Esophageal Cancer Research and Treatment (71 papers), Gastric Cancer Management and Outcomes (67 papers) and Cancer Research and Treatments (37 papers). Hideaki Shimada collaborates with scholars based in Japan, United States and China. Hideaki Shimada's co-authors include Takenori Ochiai, Hisahiro Matsubara, Hideki Hayashi, Shinichi Okazumi, Yoshihiro Nabeya, Fumio Nomura, Tooru Shiratori, Koji Oba, Takao Suzuki and Masatoshi Tagawa and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Hideaki Shimada

363 papers receiving 8.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association

2013 393 citations Hideaki Shimada et al. profile →

Peers

Countries citing papers authored by Hideaki Shimada

Since Specialization

Citations

This map shows the geographic impact of Hideaki Shimada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hideaki Shimada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hideaki Shimada more than expected).

Fields of papers citing papers by Hideaki Shimada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hideaki Shimada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hideaki Shimada. The network helps show where Hideaki Shimada may publish in the future.

Co-authorship network of co-authors of Hideaki Shimada

This figure shows the co-authorship network connecting the top 25 collaborators of Hideaki Shimada. A scholar is included among the top collaborators of Hideaki Shimada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hideaki Shimada. Hideaki Shimada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prognostic and diagnostic effects of high serum midkine levels in patients with hepatocellular carcinoma 2024 ·Oncology Letters ·(unknown), Yuichiro Otsuka, (unknown), Tetsuya Maeda, Jun Ishii, (unknown), Yu Matsumoto, Yuko Ito, Kimihiko Funahashi, Hideaki Shimada	2
2	PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays. 2024 ·Journal of Clinical Oncology ·Samuel J. Klempner, (unknown), (unknown), Matteo Fassan, Hisato Kawakami, Hideaki Shimada, Laura H. Tang, Daniel‐Christoph Wagner, Yasushi Yatabe, Alexander Savchenko, (unknown), Dorhyun Johng, Lauren Fairchild, Jing Chen, (unknown), Markus Moehler	1
3	PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays 2024 ·JCO Precision Oncology ·Samuel J. Klempner, (unknown), (unknown), Matteo Fassan, Hisato Kawakami, Hideaki Shimada, Laura H. Tang, Daniel‐Christoph Wagner, Yasushi Yatabe, Alexander Savchenko, (unknown), Dorhyun Johng, Jing Chen, (unknown), Markus Moehler	12
4	Low serum creatine kinase level is associated with poor prognosis in patients with hepatocellular carcinoma: A retrospective single‑center study 2024 ·Oncology Letters ·Yu Matsumoto, Yuichiro Otsuka, (unknown), Yuko Ito, (unknown), Jun Ishii, Tetsuya Maeda, Masaru Tsuchiya, Kimihiko Funahashi, Hideaki Shimada	0
5	Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer 2023 ·Oncology Letters ·(unknown), Takaki Hiwasa, Masaaki Ito, Mitsunori Ushigome, Hirotaka Takizawa, (unknown), (unknown), Yasuo Iwadate, Kimihiko Funahashi, Hideaki Shimada	2
6	Combinational antibody detection approach increases the clinical validity of colorectal cancer screening 2023 ·Journal of Clinical Laboratory Analysis ·Sohei Kobayashi, Takaki Hiwasa, K Kitamura, Masayuki Kano, Tyuji Hoshino, (unknown), (unknown), Masanori Seimiya, Hideaki Shimada, Fumio Nomura, Hisahiro Matsubara, Kazuyuki Matsushita	2
7	Colorectal Cancer–Derived CAT1-Positive Extracellular Vesicles Alter Nitric Oxide Metabolism in Endothelial Cells and Promote Angiogenesis 2021 ·Molecular Cancer Research ·Atsushi Ikeda, Satoshi Nagayama, (unknown), (unknown), Risa Fujii, Naomi Saichi, Satoshi Muraoka, Daisuke Saigusa, Hideaki Shimada, Yoshiharu Sakai, Koji Ueda	29
8	Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group 2021 ·Journal of Hepato-Biliary-Pancreatic Sciences ·Sohei Satoi, Naminatsu Takahara, Tsutomu Fujii, Hiroyuki Isayama, Suguru Yamada, Yasushi Tsuji, Hideyo Miyato, Hironori Yamaguchi, Tomohisa Yamamoto, Daisuke Hashimoto, So Yamaki, Yousuke Nakai, Kei Saito, Hayato Baba, Toru Watanabe, Shigeto Ishii, Masamichi Hayashi, (unknown), Hideaki Shimada, Joji Kitayama	12
9	Prognostic impact of CEA/CA19-9 at the time of recurrence in patients with gastric cancer 2021 ·Surgery Today ·(unknown), Yoko Oshima, Tatsuki Nanami, Takashi Suzuki, Satoshi Yajima, Fumiaki Shiratori, Kimihiko Funahashi, Hideaki Shimada	21
10	Anti‐FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer 2020 ·Cancer Science ·Sohei Kobayashi, Takaki Hiwasa, Takayuki Ishige, Masayuki Kano, Tyuji Hoshino, Bahityar Rahmutulla, Masanori Seimiya, Hideaki Shimada, Fumio Nomura, Hisahiro Matsubara, Kazuyuki Matsushita	5
11	Anti‐FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma 2019 ·Cancer Science ·Sohei Kobayashi, Takaki Hiwasa, Takayuki Ishige, Bahityar Rahmutulla, Masayuki Kano, Tyuji Hoshino, Toshinari Minamoto, Hideaki Shimada, Fumio Nomura, Hisahiro Matsubara, Kazuyuki Matsushita	11
12	Diagnostic and Prognostic Impact of Serum p53 Antibody Titration in Colorectal Cancer 2017 ·Takayuki Suzuki, Kimihiko Funahashi, Mitsunori Ushigome, Junichi Koike, Tetsuo Nemoto, Hideaki Shimada	4
13	Presence of Autoantibodies against Ras-like GTPases in Serum in Stage I/II Breast Cancer 2017 ·(unknown), Hideaki Ogata, (unknown), (unknown), Fumi Saito, Hideaki Shimada	4
14	Adenoviruses-mediated transduction of human oesophageal carcinoma cells with the interferon-λ genes produced anti-tumour effects 2011 ·British Journal of Cancer ·(unknown), K Kawamura, Shinya Okamoto, (unknown), M. Numasaki, Masayoshi Namba, Michio Nagata, Hideaki Shimada, Hiroshi Kobayashi, Masatoshi Tagawa	14
15	Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma 2010 ·International Journal of Cancer ·Yoshinori Suzuki, Katsuya Sakai, (unknown), Qing Xu, Takahiro Nakamura, Hideaki Shimada, Toshikazu Nakamura, Kunio Matsumoto	38
16	An Essential Role of Alternative Splicing of c-myc Suppressor FUSE-Binding Protein–Interacting Repressor in Carcinogenesis 2006 ·Cancer Research ·Kazuyuki Matsushita, Takeshi Tomonaga, Hideaki Shimada, (unknown), Morihiro Higashi, Hisahiro Matsubara, Kenichi Harigaya, Fumio Nomura, Daniel Libutti, David Levens, Takenori Ochiai	73
17	A Case of Scirrhous-Type Gastric Cancer in the Gastric Tube of a Patient Previously Treated for Thoracic Esophageal Cancer 2004 ·The Japanese Journal of Gastroenterological Surgery ·(unknown), Shinichi Okazumi, Hisahiro Matsubara, Hideaki Shimada, Takenori Ochiai	1
18	Tandem repeat polymorphism of the CYP2E1 gene: an association study with esophageal cancer and lung cancer. 2002 ·PubMed ·Sakae Itoga, Fumio Nomura, Yasuhiko Makino, Takeshi Tomonaga, Hideaki Shimada, Takenori Ochiai, Toshihiko Iizasa, Masayuki Baba, Takehiko Fujisawa, Shoji Harada	41
19	Indications and Limitations of 3-Field Lymph Node Dissection for Thoracic Esophageal Carcinoma. 1999 ·The Japanese Journal of Gastroenterological Surgery ·Miwako Arima, Yoshio Koide, Shinichi Okazumi, Hideaki Shimada, Hisahiro Matsubara, Yukimasa Miyazawa, Yutaka Funami, Takenori Ochiai	3
20	Molecular transplantation of MHC class II genes as a means for inducing transplantation tolerance in miniature swine. 1993 ·Christian LeGuern, Hideaki Shimada, David W. Emery, Sharon Germana, David H. Sachs	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact